Literature DB >> 15170038

Enhanced virulence, airway inflammation and impaired lung function induced by respiratory syncytial virus deficient in secreted G protein.

J Schwarze1, U Schauer.   

Abstract

BACKGROUND: Respiratory syncytial virus (RSV) infection can cause bronchial hyperresponsiveness and asthma exacerbations. In mice it results in airway inflammation and airway hyperresponsiveness. Since viral factors influencing these responses are not well defined, a study was undertaken to investigate the role of secreted G protein of human RSV in determining virulence, inflammatory responses, and changes in lung function.
METHODS: BALB/c mice were infected with a spontaneous mutant of RSV deficient in secreted G protein (RSV-DeltasG) or with wild type RSV (RSV-WT). Viral titres, numbers of pulmonary inflammatory cells, and concentrations of interferon (IFN)-gamma, interleukin (IL)-4, IL-5 and IL-10 in bronchoalveolar lavage (BAL) fluid were determined. Airway function was assessed at baseline and following methacholine provocation using barometric whole body plethysmography. RESULT: Following infection with RSV-DeltasG, viral titres were increased 50-fold compared with RSV-WT. Influx of eosinophils and macrophages to the lung and concentrations of IFN-gamma and IL-10 in BAL fluid were also significantly higher following infection with RSV-DeltasG. Airway function, both at baseline and after methacholine provocation, was significantly decreased following infection with RSV-DeltasG compared with RSV-WT.
CONCLUSION: Secreted G protein is likely to be a regulatory factor in RSV infection limiting infectivity of the virus, inflammatory responses in the lungs, and reduction in lung function.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15170038      PMCID: PMC1747027          DOI: 10.1136/thx.2003.017343

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  27 in total

1.  Recovery of infectious Ebola virus from complementary DNA: RNA editing of the GP gene and viral cytotoxicity.

Authors:  V E Volchkov; V A Volchkova; E Muhlberger; L V Kolesnikova; M Weik; O Dolnik; H D Klenk
Journal:  Science       Date:  2001-02-01       Impact factor: 47.728

Review 2.  Respiratory infections: their role in airway responsiveness and the pathogenesis of asthma.

Authors:  W W Busse
Journal:  J Allergy Clin Immunol       Date:  1990-04       Impact factor: 10.793

3.  CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein.

Authors:  R A Tripp; L P Jones; L M Haynes; H Zheng; P M Murphy; L J Anderson
Journal:  Nat Immunol       Date:  2001-08       Impact factor: 25.606

4.  Contribution of the respiratory syncytial virus G glycoprotein and its secreted and membrane-bound forms to virus replication in vitro and in vivo.

Authors:  M N Teng; S S Whitehead; P L Collins
Journal:  Virology       Date:  2001-10-25       Impact factor: 3.616

5.  IL-10 is necessary for the expression of airway hyperresponsiveness but not pulmonary inflammation after allergic sensitization.

Authors:  M J Mäkelä; A Kanehiro; L Borish; A Dakhama; J Loader; A Joetham; Z Xing; M Jordana; G L Larsen; E W Gelfand
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-23       Impact factor: 11.205

6.  Blocking intercellular adhesion molecule-1 on human epithelial cells decreases respiratory syncytial virus infection.

Authors:  A K Behera; H Matsuse; M Kumar; X Kong; R F Lockey; S S Mohapatra
Journal:  Biochem Biophys Res Commun       Date:  2001-01-12       Impact factor: 3.575

7.  RANTES (CCL5) production during primary respiratory syncytial virus infection exacerbates airway disease.

Authors:  Kim K Tekkanat; Hussein Maassab; Allison Miller; Aaron A Berlin; Steven L Kunkel; Nicholas W Lukacs
Journal:  Eur J Immunol       Date:  2002-11       Impact factor: 5.532

8.  Appearance of a soluble form of the G protein of respiratory syncytial virus in fluids of infected cells.

Authors:  D A Hendricks; K Baradaran; K McIntosh; J L Patterson
Journal:  J Gen Virol       Date:  1987-06       Impact factor: 3.891

9.  Respiratory syncytial virus infection and virus-induced inflammation are modified by contaminants of indoor air.

Authors:  Serene Foster; Kirk J Bedford; Melanie E L Gould; William R Coward; Colin R A Hewitt
Journal:  Immunology       Date:  2003-01       Impact factor: 7.397

10.  Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit chemokine production in activated microglia.

Authors:  Mario Delgado; G Miller Jonakait; Doina Ganea
Journal:  Glia       Date:  2002-08       Impact factor: 7.452

View more
  12 in total

Review 1.  Respiratory syncytial virus (RSV) evades the human adaptive immune system by skewing the Th1/Th2 cytokine balance toward increased levels of Th2 cytokines and IgE, markers of allergy--a review.

Authors:  Yechiel Becker
Journal:  Virus Genes       Date:  2006-10       Impact factor: 2.332

Review 2.  Animal models of human respiratory syncytial virus disease.

Authors:  Reinout A Bem; Joseph B Domachowske; Helene F Rosenberg
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2011-05-13       Impact factor: 5.464

3.  A highly attenuated recombinant human respiratory syncytial virus lacking the G protein induces long-lasting protection in cotton rats.

Authors:  Myra N Widjojoatmodjo; Jolande Boes; Marleen van Bers; Yvonne van Remmerden; Paul J M Roholl; Willem Luytjes
Journal:  Virol J       Date:  2010-06-02       Impact factor: 4.099

Review 4.  Understanding the mechanisms of viral induced asthma: new therapeutic directions.

Authors:  Nicole G Hansbro; Jay C Horvat; Peter A Wark; Philip M Hansbro
Journal:  Pharmacol Ther       Date:  2008-01-29       Impact factor: 12.310

5.  A chimeric A2 strain of respiratory syncytial virus (RSV) with the fusion protein of RSV strain line 19 exhibits enhanced viral load, mucus, and airway dysfunction.

Authors:  Martin L Moore; Michael H Chi; Cindy Luongo; Nicholas W Lukacs; Vasiliy V Polosukhin; Matthew M Huckabee; Dawn C Newcomb; Ursula J Buchholz; James E Crowe; Kasia Goleniewska; John V Williams; Peter L Collins; R Stokes Peebles
Journal:  J Virol       Date:  2009-02-11       Impact factor: 5.103

6.  The secreted form of respiratory syncytial virus G glycoprotein helps the virus evade antibody-mediated restriction of replication by acting as an antigen decoy and through effects on Fc receptor-bearing leukocytes.

Authors:  Alexander Bukreyev; Lijuan Yang; Jens Fricke; Lily Cheng; Jerrold M Ward; Brian R Murphy; Peter L Collins
Journal:  J Virol       Date:  2008-10-08       Impact factor: 5.103

7.  The cysteine-rich region and secreted form of the attachment G glycoprotein of respiratory syncytial virus enhance the cytotoxic T-lymphocyte response despite lacking major histocompatibility complex class I-restricted epitopes.

Authors:  Alexander Bukreyev; Maria Elina Serra; Federico R Laham; Guillermina A Melendi; Steven R Kleeberger; Peter L Collins; Fernando P Polack
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

Review 8.  Respiratory infections and asthma.

Authors:  Girolamo Pelaia; Alessandro Vatrella; Luca Gallelli; Teresa Renda; Mario Cazzola; Rosario Maselli; Serafino A Marsico
Journal:  Respir Med       Date:  2005-11-09       Impact factor: 3.415

9.  Long-term activation of TLR3 by poly(I:C) induces inflammation and impairs lung function in mice.

Authors:  Nicole C Stowell; Jonathan Seideman; Holly A Raymond; Karen A Smalley; Roberta J Lamb; Devon D Egenolf; Peter J Bugelski; Lynne A Murray; Paul A Marsters; Rachel A Bunting; Richard A Flavell; Lena Alexopoulou; Lani R San Mateo; Don E Griswold; Robert T Sarisky; M Lamine Mbow; Anuk M Das
Journal:  Respir Res       Date:  2009-06-01

10.  Human metapneumovirus glycoprotein G inhibits innate immune responses.

Authors:  Xiaoyong Bao; Tianshuang Liu; Yichu Shan; Kui Li; Roberto P Garofalo; Antonella Casola
Journal:  PLoS Pathog       Date:  2008-05-30       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.